Trevena (NASDAQ:TRVN) Shares Cross Above Fifty Day Moving Average – Here’s Why

Shares of Trevena, Inc. (NASDAQ:TRVN) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.80 and traded as high as $1.83. Trevena shares last traded at $1.76, with a volume of 6,213 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Trevena in a research report on Thursday, November 14th. StockNews.com assumed coverage on Trevena in a research note on Saturday. They issued a “sell” rating on the stock.

Trevena Trading Down 1.4 %

The company’s fifty day moving average is $1.80 and its 200-day moving average is $4.11. The firm has a market capitalization of $1.52 million, a P/E ratio of -0.04 and a beta of 1.08.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million for the quarter. On average, equities research analysts anticipate that Trevena, Inc. will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.